RxDoctor Payments Data

Nikhil Meena, MD

Pulmonary Disease · Little Rock, ARNPI 1023232287

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (51.8%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 86.7% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2022 at $31,752 and has fallen 96.8% since, to $1,009 in 2025. Among pulmonary disease clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$62,848in general payments, 2019–2025

Across 190 payments — averaging $330.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$55K
  • Pinnacle Biologics, Inc$4K
  • Pulmonx Corporation$849
  • Olympus Corporation Of The Americas$740
  • Johnson & Johnson$676
  • Boston Scientific$614
  • plus $1K from 9 others
$511,499in research payments, 2019–2025

Across 27 payments — averaging $18,944 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$351K
  • Genentech, Inc.$161K

What the payments were for

  • Speaking & faculty fees$2,3004%
  • Travel & lodging$21,95135%
  • Food & beverage$6,03510%
  • Education$32,54852%
  • Gifts$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$62,848 in reported general payments places this provider in the 95th percentile of 102 pulmonary disease providers in Arkansas.

See all pulmonary disease providers in Arkansas

Medicare billing

Part B allowed, 2024
$130,670
Medicare patients
383
Services billed
1,146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav27$250
Prednisone47$76

Paid to pharmacies, not to this prescriber.

Other pulmonary disease in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →